

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1617

Coutre, Steven

Examiner: Jean-Louis, Samira

U.S. APPLICATION NO: 10/560669

FILED: March 23, 2007

FOR: New Pharmaceutical Uses of Staurosporine Derivatives

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- supplemental to the Information Disclosure Statement filed April 19, 2007,
- within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required.
- before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

- This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).
- A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

in accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



George Dohmann  
Attorney for Applicant  
Reg. No. 33,593

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-7824

Date: August 6, 2009